Abstract
Pregabalin is a gamma-aminobutyric acid (GABA) derivative that was commercially approved by the Food and Drug Administration (FDA) in 2004. It is commonly used in the treatment of diabetic neuropathy, peripheral neuropathy, and spinal cord injury. We present the case of a 36-year-old Caucasian male double lung transplant recipient who presented with an 18-month history of fatigue and muscle weakness. He had elevated creatinine kinase level and his muscle biopsy showed evidence of drug-induced myopathy that improved after the cessation of pregabalin. We present a case of drug-induced myopathy as a rare complication of pregabalin therapy in a double lung transplant recipient.
Document Type
Article
Publication Date
12-6-2020
Digital Object Identifier (DOI)
https://doi.org/10.7759/cureus.11935
Repository Citation
Hegde, Vishwajit; Shekar, Nidhi; Garrett, Filip G.; Baz, Maher A.; and Anstead, Michael I., "Pregabalin-Induced Myopathy in a Double Lung Transplant Recipient" (2020). Internal Medicine Faculty Publications. 227.
https://uknowledge.uky.edu/internalmedicine_facpub/227
Notes/Citation Information
Published in Cureus, v. 12, issue 12, e11935.
© Copyright 2020 Hegde et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.